supernus pharmaceuticals

News

Supernus To Acquire Sage

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for $8.50 a share in a deal worth an initial $561 million.The terms of the deal also include one non-tradable contingent value right (CVR) payable upon achieving certain sales goals,

Zacks.com on MSN · 14h

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Seeking Alpha · 1d

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential. Read my analysis on this acquisition.

14h

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

BioSpace1d

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

Fierce Pharma1d

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

pharmaphorum1d

After rebuffing Biogen, Sage pairs off with Supernus

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

TMCnet1d

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage shareholders. Under the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results